Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 3/20 | 0.48 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29141941 | 0.87 | ADAMTS4 (0.64) | SLC1A3SLC1A2SLC1A1MMP2CA12 | |
| SCHEMBL7872813 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL945862 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL3415855 | 0.82 | GBA1 (0.61) | SMN1; SMN2SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL11512348 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL4714253 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL6006659 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL8648587 | 0.80 | SLC1A2 (0.76) | SLC1A3SLC1A2SLC1A1MMP2ADAMTS4 | |
| SCHEMBL14701615 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL7791079 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2SLC1A3SLC1A2SLC1A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | SMN1; SMN2 4010/4885SLC1A3 2390/4885SLC1A2 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.